Funding
CorporateGovernance
For 2024, the total budget of the European Medicines Agency amounts to €478.5 million. Around 92.4% of the Agency’s budget derives from fees and charges, 7.3% from the European Union (EU) contribution for public-health issues and 0.3% from other sources.
Of the total budget in 2024:
- approximately €441.9 million will come from fees and charges levied for regulatory services;
- approximately €34.8 million is expected in income from the EU, mainly to support the policies for orphan and paediatric medicines, advanced therapies and micro, small and medium-sized enterprises.
Fees from industry
The Agency charges fees to companies for the evaluation of applications for marketing authorisation and for monitoring the safety of medicines across their life cycle. It also charges fees for services related to the marketing of medicines in the EU in areas such as scientific advice, inspections and the establishment of maximum residue limits.
For more information, see Fees payable to EMA.
The Agency co-ordinates the scientific evaluation of applications and related work with the national medicines regulatory authorities in the EU Member States.
The Agency compensates the national authorities for this work and for the involvement of their staff members in the Agency’s scientific committees, working groups and other activities.
In 2024, it is estimated that €174.8 million will be paid to the national competent authorities (national regulatory agencies) from the Agency’s budget.